Recently, Benson et al. reported that an acylated peptide analog of oxyntomodulin administered for 12 or 16 weeks in T2DM patients induced HbA1c reduction from baseline ranged from −1.56% to −2.16% in OXM-treated group versus −0.43% to −0.70% in control subjects, and mean body weight changes from baseline ranged from −2.30 kg to −11.24 kg in the treated group versus −0.35 kg to −2.03 kg in control subjects [283]. This evidence concerns the gene GCG and type 2 diabetes mellitus.